AtriCure (ATRC) Q3 FY2026 earnings: revenue $154 million, up 15.0% on the year

AtriCure, Inc. (ATRC) reported revenue of $154 million for Q3 FY2026, the quarter ended 30 September 2026, up 15.0% on the same quarter a year earlier. Net income was $4 million, and diluted earnings per share $0.08. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$154 million

+15.0% on the year · +0.6% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

2.8%

0.2% a year earlier

Q4 FY2024Q3 FY2026

Net income

$4 million

-54.6% on the quarter

Q4 FY2024Q3 FY2026

Diluted EPS

$0.08

-55.6% on the quarter

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 3 raised, 1 narrowed.

Revenue rose 15.0% to $154.5 million: Worldwide revenue was $154.5 million, up from $134.3 million in the third quarter of 2025, with growth in both the United States and international segments.
Adjusted EBITDA up 51% year over year: Adjusted EBITDA was $26.8 million, up $9.0 million from the third quarter of 2025 and slightly below the $27.3 million reported for the second quarter.
U.S. revenue up 17.1%: U.S. revenue was $128.0 million, an increase of $18.7 million from the third quarter of 2025. Growth came from pain management, open ablation and appendage management.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	154	154	134	+0.6%	+15.0%
Cost of revenue	35.1	35.0	32.9	+0.4%	+6.6%
Gross profit	119	119	101	+0.6%	+17.8%
Gross margin	77.3%	77.2%	75.5%
Research and development	32.1	26.4	22.9	+21.6%	+40.3%
Selling, general and administrative	82.9	82.6	78.2	+0.4%	+5.9%
Operating income	4.4	9.7	0.2	-55.0%	+1,992.8%
Operating margin	2.8%	6.3%	0.2%
Interest expense	1.6	1.3	1.5	+22.5%	+9.9%
Pre-tax income	4.0	9.4	-0.1	-57.4%
Income tax	-0.0	0.5	0.2
Effective tax rate	-1.2%	5.0%	n/a
Net income	4.1	9.0	-0.3	-54.6%
Net margin	2.6%	5.8%	-0.2%
Diluted EPS	$0.08	$0.18	-$0.01	-55.6%

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	30.3	22.2	26.7	+36.6%	+13.5%
Capital expenditure	6.4	3.8	2.6	+69.6%	+145.2%
Free cash flow	23.9	18.4	24.1	+29.9%	-0.7%
Free cash flow margin	15.5%	12.0%	18.0%
Cash from investing	-10.9	-3.8	-2.6
Cash from financing	-0.0	3.3	6.0
Depreciation and amortisation	5.5	5.3	5.2	+3.2%	+5.9%
Share-based compensation	12.5	12.3	12.4	+1.3%	+0.4%
Diluted shares, weighted	50m	49m	48m	+2.0%	+4.0%
Shares outstanding at period end	51m	51m	50m	+0.1%	+2.4%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	533	516	477	+3.3%	+11.9%
Debt	61.0	61.0	61.9	0.0%	-1.4%
Operating lease liabilities	4.4	4.8	5.6	-7.7%	-20.6%
Finance lease liabilities	27.7	5.3	6.3	+425.2%	+338.6%
Other liabilities	91.2	89.2	85.2	+2.3%	+7.0%
Total liabilities and equity	718	677	635	+6.0%	+12.9%
Goodwill	235	235	235	0.0%	0.0%
Intangible assets	40.9	43.3	50.1	-5.5%	-18.5%
Cash and equivalents	187	168	148	+11.5%	+26.5%
Receivables	76.1	80.0	63.0	-4.8%	+20.9%
Inventory	87.3	83.9	79.0	+4.0%	+10.6%
Other assets	91.4	66.9	60.7	+36.6%	+50.5%
Total assets	718	677	635	+6.0%	+12.9%

Questions

What was AtriCure's revenue in Q3 FY2026?

AtriCure (ATRC) reported revenue of $154 million for Q3 FY2026, the quarter ended 30 September 2026, up 15.0% on the same quarter a year earlier.

How much did AtriCure earn in Q3 FY2026?

Net income for Q3 FY2026 was $4 million, and diluted earnings per share $0.08.

When did AtriCure report Q3 FY2026 results?

AtriCure filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	73.2	74.6	84.5	83.2	88.0	93.5	101	98.3	107	109	116	116	124	124	136	134	140	141	154	154
Cost of revenue	18.2	19.0	21.0	21.5	22.9	23.9	23.8	24.4	26.7	27.6	29.4	29.1	31.7	31.0	34.7	32.9	35.2	31.9	35.0	35.1
Gross profit	55.0	55.6	63.5	61.7	65.1	69.6	77.1	73.9	79.8	81.3	86.8	86.8	92.6	92.6	101	101	105	109	119	119
Gross margin	75%	75%	75%	74%	74%	74%	76%	75%	75%	75%	75%	75%	75%	75%	75%	75%	75%	77%	77%	77%
R&D	13.8	13.6	14.8	15.2	13.7	15.3	17.4	20.4	20.8	19.8	20.4	21.0	35.0	22.5	29.3	22.9	24.5	24.2	26.4	32.1
SG&A	48.6	56.1	62.4	57.3	55.5	60.1	63.8	61.6	67.7	72.3	73.6	73.2	72.2	76.1	78.4	78.2	78.3	84.5	82.6	82.9
Operating income	-12.5	-14.2	-13.7	-10.7	-4.1	-5.8	-4.1	-8.1	-8.7	-10.9	-7.2	-7.4	-14.5	-6.0	-6.2	0.2	2.5	0.5	9.7	4.4
Operating margin	-17%	-19%	-16%	-13%	-5%	-6%	-4%	-8%	-8%	-10%	-6%	-6%	-12%	-5%	-5%	0%	2%	0%	6%	3%
Interest expense	1.1	1.0	1.1	1.3	1.6	1.6	1.7	1.8	1.8	1.7	1.6	1.7	1.5	1.4	1.5	1.5	1.5	1.3	1.3	1.6
Pre-tax income	-13.7	-15.1	-14.8	-12.2	-4.0	-6.4	-5.0	-9.0	-9.4	-13.1	-7.8	-7.5	-15.3	-6.5	-5.9	-0.1	2.4	0.4	9.4	4.0
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	26%	73%	5%	-1%
Net income	-13.7	-15.2	-14.8	-12.3	-4.2	-6.5	-5.1	-9.1	-9.8	-13.3	-8.0	-7.9	-15.6	-6.7	-6.2	-0.3	1.8	0.1	9.0	4.1
Net margin	-19%	-20%	-18%	-15%	-5%	-7%	-5%	-9%	-9%	-12%	-7%	-7%	-13%	-5%	-5%	-0%	1%	0%	6%	3%
Diluted EPS	-$0.28	-$0.33	-$0.32	-$0.27	-$0.09	-$0.14	-$0.11	-$0.20	-$0.21	-$0.28	-$0.17	-$0.17	-$0.33	-$0.14	-$0.13	-$0.01	$0.04	$0.00	$0.18	$0.08
Operating cash flow	0.3	-24.6	4.2	-1.8	0.0	-4.1	3.0	1.5	4.0	-21.0	7.4	20.0	5.8	-11.0	21.6	26.7	20.0	-4.0	22.2	30.3
Capital expenditure	2.7	3.4	4.2	5.1	4.2	2.5	3.1	3.6	2.8	2.8	2.4	3.6	2.7	2.2	2.7	2.6	1.6	3.9	3.8	6.4
Free cash flow	-2.4	-28.0	0.0	-6.9	-4.1	-6.6	-0.1	-2.1	1.2	-23.8	5.0	16.4	3.1	-13.2	19.0	24.1	18.4	-7.8	18.4	23.9
Shares outstanding	46m	46m	46m	46m	47m	47m	47m	47m	48m	48m	49m	49m	49m	49m	50m	50m	50m	51m	51m	51m
Filing	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.